GSK & Pfizer suma y...pierde Chairman (Philip Hampton)

.

GlaxoSmithKline Plc Chairman Philip Hampton will step down after more than three and a half years in the role, as Britain's biggest drugmaker prepares to split its business into two.

The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products.

Ver:

GSK and Pfizer to create consumer healthcare JV

Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction.

"Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement. 

Ver tambén:
GlaxoSmithKline / Pfizer Consumer Merger...rational.

Hampton, aged 65, was paid a sum of 700,000 pounds ($900,550), of which he elected to take 25 percent in GSK shares, according to the company's 2017 annual report.

He took the top job at GSK at a testing time - just after a profit warning in 2014 due to weak sales of its core respiratory drugs.

Mas